Albert Labs has appointed Professor Robert Britton and Dr Ricardo Jorge Dinis-Oliveira to its scientific advisory board (SAB).
The two renowned advisors will be bringing a wealth of knowledge and experience to the Albert Labs SAB.
The company has appointed Professor Robert Britton, a natural product chemist, BSc, PhD, of Simon Fraser University, who is a well-published natural product chemist with globally recognised expertise in natural product drug discovery, medicinal chemistry and cancer therapeutics.
Renowned toxicologist and pharmacologist Dr Jorge Dinis-Oliveira, PhD, European PhD, DSc, has also been appointed, whose focus is in the areas of toxicology and the pharmacology of psychoactive substances and medicines, focusing on their preclinical and clinical development stages.
CEO of Albert Labs, Dr Michael Raymont, commented: “We are delighted to welcome Professor Robert Britton and Dr Dinis-Oliveira to our scientific advisory board.
“Their exceptional expertise in natural product medicines and their depth of knowledge in toxicology and pharmacology complement the expertise of our other SAB members.
“Improving drug discovery, and gaining a better understanding and depth of these compounds’ pharmacodynamics and toxicology are critical to building value for Albert Labs shareholders as we advance toward our goal of delivering safe and effective drugs to revolutionise mental health treatment.”
With a particular focus on oncology, Britton creates new tools for late-stage modification of drug leads, new processes for improving the manufacture of drugs, and new strategies for synthesising structurally complex natural products.
Prior to his academic career, Britton was a senior scientist in the Process Research Group at Merck.
Dinis-Oliveira is a member of the editorial boards and ambassador to several international scientific journals and is well-published, having authored more than 170 published articles in international indexed journals and peer-reviewed.
Additionally, Dinis-Oliveira acted author of some thirty-six book chapters, four books and four National and three International patents. In 2021 he was included on the world’s top 2 per cent of Scientists List, which ranks the most highly cited scientists globally.
He has a passion for the pharmacology of psychoactive substances and has recently taken on the position of Editor-in-Chief of the newly formed journal, “Psychoactives”, an International, peer-reviewed, journal on psychoactive substances.
Professor Robert Britton said: “I’m excited to be working with Albert Labs. Fungi have been an important source of new medicines and are, on the whole, pharmaceutically prolific and extremely promising.
“Albert Labs’ scientific approach to natural product drug discovery and development is a promising step towards the creation of new medications for patients with urgent unmet needs and developing a future pipeline of products for wider indications.”
Dinis-Oliveira commented: “My team and I will complete thorough toxicological & pharmacological testing to ensure that all of Albert Labs’ clinical work, with KRN-101, is delivered safely and effectively.
“I am looking forward to assisting a company that will be safely administering psilocybin as a complement to psychotherapy and other pharmacological chemical treatments for people with urgent and unmet needs. This is especially the case for patients who are refractory to conventional treatments.”
